1 Kipps E,Tan DS,Kaye SB.Meeting the challenge of ascites in ovarian cancer:New avenues for therapy and research[J].Nat Rev Cancer,2013,13(4):273-282. 2 Ahmed N,Stenvers KL.Getting to know ovarian cancer ascites:Opportunities for targeted therapy-based translational research[J].Front Oncol,2013,25(3):256. 3 Takeichi M.Dynamic contacts:Rearranging adherens junctions to drive epithelial remodeling[J].Nat Rev Mol Cell Biol,2014,15(6):397-410. 4 Miow QH,Tan TZ,Ye J,et al.Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer[J].Oncogene,2015,34(15):1899-1907. 5 Reddy P,Liu,L,Ren,C,et al.Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells[J].Endocrinol,2005,19(10):2564-2578. 6 Dong LL,Liu L,Ma CH,et al.E-cadherin promotes proliferation of human ovarian cancer cells in vitro via activating MEK/ERK pathway[J].Acta Pharmacol Sin,2012,33(6):817-822. 7 Cheung LW,Leung PC,Wong AS.Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer[J].Oncogene,2010,29(16):2427-2440. 8 Cheung LW,Mak AS,Cheung AN,et al.P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin[J].Oncogene,2011,30(26):2964-2974. 9 Cheung LW,Yung S,Chan TM,et al.Targeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion[J].Mol Ther,2013,21(1):78-90. 10 Ip CK,Yung S,Chan TM,et al.p70S6 kinase drives ovarian cancer metastasis through multicellular spheroid-peritoneum interaction and P-cadherin/β1 integrin signaling activation[J].Oncotarget,2014,5(19):9133-9149. 11 Barczyk M,Carracedo S,Gullberg D.Integrins[J].Cell Tissue Res,2010,339(1):269-280. 12 Zhao X,Guan JL.Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis[J]Adv Drug Deliv Rev,2011,63(8):610-615. 13 Yousif NG.Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation ofFAK-PI3K/Akt pathway[J].Cell Biol Int,2014,38(1):85-91. 14 Desgrosellier JS,Cheresh DA.Integrins in cancer:Biological implications and therapeutic opportunities[J].Nat Rav Cancer,2010,10(1):9-22. 15 Ivaska J,Heino J.Cooperation between integrins and growth factor receptors in signaling and endocytosis[J].Annu Rev Cell Dev Biol,2011,27:291-320. 16 Jiao Y,Ou W,Meng F,et al.Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation[J].Mol Cancer,2011,10:125. 17 Alper O,Bergmann-Leitner ES,Bennett TA,et al.Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells[J].J Natl Cancer Inst,2001,93(18):1375-1384. 18 Sawada K,Radjabi AR,Shinomiya N,et al.c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination andinvasion[J].Cancer Res,2007,67(4):1670-1679. 19 Mitra AK,Sawada K,Tiwari P,et al.Ligand-independent activation of c-Met by fibronectin and α5β1-integrin regulates ovarian cancer invasion and metastasis[J].Oncogene,2011,30(13):1566-1576. 20 Kwon Y,Smith BD,Zhou Y,et al.Effective inhibition of c-MET-mediated signaling,growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment[J].Oncogene,2015,34(2):144-153. 21 Moran-Jones K,Brown LM,Samimi G.INC280,an orally available small molecule inhibitor of c-MET,reduces migration and adhesion in ovarian cancer cell models[J].Sci Rep,2015,5:11749. 22 Mu J,Abe Y,Tsutsui T,et al.Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity[J].Jpn J Cancer Res,1996,87(9):963-971. 23 Brown M,Black JR,Sharma R,et al.Gene of the month:Axl[J].J Clin Pathol,2016,69(5):391-397. 24 Zhang Z,Lee JC,Lin L,et al.Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer[J].Nat Genet,2012,44(8):852-860. 25 Rankin EB,Fuh KC,Taylor TE,et al.Axl is an essential factor and therapeutic target for metastatic ovarian cancer[J].Cancer Res,2010,70(19):7570-7579. 26 Rea K,Pinciroli P,Sensi M,et al.Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome[J].Oncotarget,2015,6(31):30859-30875. 27 Lualdi M,Pedrini E,Rea K,et al.Pleiotropic modes of action in tumor cells of RNASET2,an evolutionary highly conserved extracellular RNase[J].Oncotarget,2015,6(10):7851-7865. 28 Yin F,Liu L,Liu X,et al.Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer[J].Oncol Rep,2014,32(1):362-372. |